|Table of Contents|

Correlation between serum PD-L1 content and T lymphocyte immune function in patients with esophageal squamous cell carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 07
Page:
1241-1246
Research Field:
Publishing date:

Info

Title:
Correlation between serum PD-L1 content and T lymphocyte immune function in patients with esophageal squamous cell carcinoma
Author(s):
CUI Wenxuan1; ZHAO Wei1; TIAN Guo2; JIAO Wenjing1; YANG Qing1; GUO Xiujuan1; ZHANG Jinyan1; MA Ming1
1.Department of Clinical Laboratory；2.Record Room,the Fourth Hospital of Hebei Medical University,Hebei Shijiazhuang 050011,China.
Keywords:
esophageal squamous cell carcinoma; programmed death-ligand 1; T lymphocyte subsets; immune function
PACS:
R735.1
DOI:
10.3969/j.issn.1672-4992.2023.07.011
Abstract:
Objective:To investigate the correlation between serum programmed death-ligand 1(PD-L1) and T lymphocyte immune function in patients with esophageal squamous cell carcinoma(ESCC).Methods：62 patients with ESCC who were newly diagnosed in our hospital from August 2021 to January 2022 were enrolled as ESCC group,and 29 patients in the control group were from relatively healthy people.The two independent samples Wilcoxon rank sum test was uesd to compare the levels of serum PD-L1 and T lymphocyte subsets between the two groups and the differences of these indexes in different clinical stages in the ESCC group.The prediction value of the discrepant indexes in clinical stages on the clinical progress of ESCC was evaluated by the ROC curve.The correlation between serum PD-L1 level and clinical pathological features in ESCC patients was analyzed by χ2 test.Two independent samples Wilcoxon rank sum test was used to compare the levels of T lymphocyte subsets between the high and low PD-L1 groups.Results：The level of PD-L1 in ESCC group was significantly higher than that in control group,and the level of PD-L1 in ESCC patients in stage Ⅲ-Ⅳ was significantly higher than that in stage Ⅰ-Ⅱ(P<0.05).The percentage of CD4+PD-1+T cells in ESCC group was significantly higher than that in control group(P<0.05).CD3+T cell absolute count,CD4+T cell absolute count,CD4+CD28+T cell absolute count,CD8+CD28+T cell percentage and absolute count were significantly lower than those of control group(P<0.05).The percentage of CD4+PD-1+T cells in stage Ⅲ - Ⅳ of ESCC group was significantly higher than that in stage Ⅰ-Ⅱ. The percentage and absolute value of CD4+CD28+T cells were significantly lower than those of stage Ⅰ-Ⅱ(P<0.05).The level of serum PD-L1 was closely related to the clinical progress of ESCC patients,and had a high predictive value(P<0.05).The percentage of CD4+PD-1+T cells in high PD-L1 group was significantly higher than that in low PD-L1 group(P<0.05),while the percentage and absolute count of CD4+CD28+T cells,percentage and absolute count of CD8+CD28+T cells were significantly lower than those of the low value group(P<0.05).Conclusion：Serum PD-L1 level is closely related to the levels of T lymphocyte surface antigens PD-1 and CD28,which may be one of the important factors in inhibiting T lymphocyte immune function and promoting immune escape of ESCC cells.

References:

［1］SIEGEL RL,MILLER KD,FUCHS HE,et al.Cancer statistics, 2022［J］.CA Cancer J Clin,2022,72(1):7-33.
［2］CAO W,CHEN HD,YU YW,et al.Changing profiles of cancer burden worldwide and in China:A secondary analysis of the global cancer statistics 2020［J］.Chin Med J(Engl),2021,134(7):783-791.
［3］UHLENHOPP DJ,THEN EO,SUNKARA T,et al.Epidemiology of esophageal cancer:Update in global trends,etiology and risk factors［J］.Clin J Gastroenterol,2020,13(6):1010-1021.
［4］王程浩,韩泳涛.2020年中国临床肿瘤学会《食管癌诊疗指南》解读［J］.肿瘤预防与治疗,2020,33(4):285-290. WANG CH,HAN YT.Interpretation of esophageal Cancer Diagnosis and Treatment Guidelines of the Chinese Society of Clinical Oncology in 2020［J］.Cancer Prevention and Treatment,2020,33(4):285-290.
［5］ZHANG C,WANG F,SUN N,et al.The combination of novel immune checkpoints HHLA2 and ICOSLG:A new system to predict survival and immune features in esophageal squamous cell carcinoma［J］.Genes Dis,2020,9(2):415-428.
［6］姜茹斌,张凯瑞,葛源.肿瘤细胞中PD-L1表达调控机制的研究进展［J］.中国细胞生物学学报,2021,43(12):2421-2432. JIANG RB,ZHANG KR,GE Y.Research progress on the regulation mechanism of PD-L1 expression in tumor cells［J］.Chinese Journal of Cell Biology,2021,43(12):2421-2432.
［7］姜建春,姜新华,周群英,等.结核性胸膜炎患者胸腔积液及血清PD-1/PD-L1通路蛋白表达及其诊断价值［J］.中华医院感染学杂志,2021,31(19):2954-2958. JIANG JC,JIANG XH,ZHOU QY,et al.Protein expression of PD-1/PD-L1 pathway in pleural effusion and serum of patients with tuberculous pleurisy and its diagnostic value［J］.Chinese Journal of Nosocomiology,2021,31(19):2954-2958.
［8］SHIRAISHI T,TOYOZUMI T,SAKATA H,et al.Soluble PD-L1 concentration is proportional to the expression of PD-L1 in tissue and is associated with a poor prognosis in esophageal squamous cell carcinoma［J］.Oncology,2022,100(1):39-47.
［9］LI JH,MA WJ,WANG GG,et al.Clinicopathologic significance and prognostic value of programmed cell death ligand 1(PD-L1) in patients with hepatocellular carcinoma:A Meta-analysis［J］.Front Immunol,2018,9:2077.
［10］LI Q,ZHOU ZW,LU J,et al.PD-L1 P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer［J］.Mol Ther,2022,30(2):621-631.
［11］马银娟,杨柯,杨夏影,等.初诊多发性骨髓瘤患者T细胞亚群和骨髓瘤细胞中PD-1、PD-L1及PD-L2的表达与意义［J］.肿瘤防治研究,2022,49(1):40-45. MA YJ,YANG K,YANG XY,et al.Expression and significance of PD-1,PD-L1 and PD-L2 in T cell subsets and myeloma cells of newly diagnosed patients with multiple myeloma［J］.Cancer Prevention and Treatment,2022,49(1):40-45.
［12］YU H,BOYLE TA,ZHOU CC,et al.PD-L1 expression in lung cancer［J］.J Thorac Oncol,2016,11(7):964-975.
［13］HAN YY,LIU DD,LI LH.PD-1/PD-L1 pathway:Current researches in cancer［J］.Am J Cancer Res,2020,10(3):727-742.
［14］BABA Y,NOMOTO D,OKADOME K,et al.Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma［J］.Cancer Sci,2020,111(9):3132-3141.
［15］HOFMEYERR KA,JEON H,ZANG X.The PD-1/PD-L1(B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion［J］.J Biomed Biotechnol,2011,2011:451694.
［16］ZUAZO M,ARASANZ H,BOCANEGRA A,et al.Systemic CD4 immunity as a key contributor to PD-L1/PD-1 blockade immunotherapy efficacy［J］.Front Immunol,2020,11:586907.
［17］FU R,JING CQ,LI XR,et al.Prognostic significance of serum PD-L1 level in patients with locally advanced or metastatic esophageal squamous cell carcinoma treated with combination cytotoxic chemotherapy［J］.Cancer Manag Res,2021,13:4935-4946.
［18］李静梅,汪维鹏.B7/CD28家族分子的糖基化研究进展［J］.现代免疫学,2020,40(2):153-157. LI JM,WANG WP.Advances in glycosylation of B7/CD28 family molecules［J］.Modern Immunology,2020,40(2):153-157.
［19］MAYOUX M,ROLLER A,PULKO V,et al.Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy［J］.Sci Transl Med,2020,12(534):eaav7431.
［20］HUI E,CHENG J,ZHU J,et al.T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition［J］.Science,2017,355(6332):1428-1433.
［21］ZHENG S,LUO X,DONG C,et al.A B7-CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma［J］.Int J Cancer,2018,143(10):2592-2601.

Memo

Memo:
河北省财政厅政府资助临床医学优秀人才课题（编号：冀财预复［2020］397号）；河北省三三三人才工程资助课题（编号：A20203003）；河北省医学科学研究课题（编号：20201094）
Last Update: 2023-02-28